research peptides FAQ

Yes—NAD+ elevation is transient. With a half-life of 4–6 hours, missing doses allows NNMT activity to resume and NAD+ levels to drop. The fat oxidation shift requires sustained AMPK activation, which depends on consistent NAD+ availability. Research protocols that use intermittent dosing (e.g., 3–4 days per week instead of daily) show reduced efficacy compared to daily administration. If compliance is a constraint, researchers should consider whether a peptide with a longer half-life (like a GLP-1 agonist) is better suited to the study design—5-amino-1MQ demands daily adherence.

Use AOD-9604. GLP-1 agonists reduce caloric intake by 20–30%, which makes it impossible to separate direct lipolytic effects from deficit-driven fat loss. AOD-9604 activates hormone-sensitive lipase directly at the adipocyte level through beta-3 adrenergic signalling. Appetite remains unaffected, allowing you to measure fat oxidation in controlled-intake protocols without the confounding variable of reduced feeding. This is the primary reason metabolic researchers select AOD-9604 over incretin-based peptides when intake must remain constant.

Segment storage by temperature sensitivity. Peptides require consistent 2–8°C refrigeration post-reconstitution with zero temperature excursions. Even brief warming to 15°C can initiate irreversible protein unfolding. Lipo-C is more forgiving: while refrigeration at 2–8°C is recommended, the small-molecule components (methionine, choline, inositol) remain chemically stable if the vial reaches 12–15°C briefly during handling. Store peptides on the bottom shelf where temperature is most stable; Lipo-C can occupy middle or upper shelves. Never assume storage protocols are interchangeable between lipotropics and peptides. Peptide instability is the single most common reason for irreproducible results in metabolic research.

Include AOD-9604 as the beta-3 adrenergic pathway representative, semaglutide or tirzepatide as the incretin pathway representative, and ipamorelin as the GH secretagogue pathway representative. That triad covers the three major mechanistic approaches to body composition modulation: direct adipocyte activation (AOD-9604), appetite suppression via hypothalamic signalling (GLP-1 agonists), and indirect lipolysis through GH-mediated HSL activation (secretagogues). When you compare AOD-9604 to other research peptides in this framework, the pathway selectivity becomes immediately obvious. And the data shows which mechanism performs best under specific experimental constraints.

Use both peptides in parallel. ARA-290's anti-apoptotic mechanism and BPC-157's angiogenic mechanism operate through independent pathways with no documented receptor competition. Research from the Journal of Cellular Physiology (2018) demonstrated additive benefits when cytoprotective and regenerative signaling are activated simultaneously in diabetic wound models. The practical protocol: administer ARA-290 at 4mg three times weekly for neural protection, and BPC-157 at 250–500mcg daily for structural repair. No timing separation is required. Subcutaneous injections can be given at different sites during the same session.

No—or at least, not through its primary mechanism. If NNMT expression is already low (e.g., in lean, metabolically healthy subjects), blocking it further won't produce the NAD+ elevation that drives fat oxidation. The Cell Metabolism study used diet-induced obese mice, where NNMT expression is elevated—that's the population where the intervention matters. Research examining 5-amino-1MQ in lean subjects would likely show minimal effect because the enzymatic bottleneck isn't present. This is why NNMT inhibition is being explored for obesity and metabolic dysfunction specifically, not as a general metabolic enhancer in already-optimized systems.

Kisspeptin and growth hormone secretagogues act on independent receptor systems with no pharmacological interaction. Combining kisspeptin with GHRP-2 or MK-677 in a research protocol wouldn't produce receptor competition or overlapping signaling interference. However, the biological outcomes are orthogonal: kisspeptin elevates gonadotropins (LH/FSH), while GHRPs elevate GH and IGF-1. Whether that combination serves a specific research objective depends on the hypothesis. There's no synergistic effect between reproductive axis stimulation and direct GH pathway activation.

Don't expect measurable collagen deposition or wound closure acceleration. VIP inhibits pro-inflammatory signaling but doesn't stimulate fibroblast proliferation, VEGF release, or extracellular matrix synthesis. The mechanisms that drive tissue repair. A 2021 study in Wound Repair and Regeneration found VIP reduced inflammatory cell infiltration at wound sites by 54% but did not improve wound closure rate compared to saline control. If tissue repair is the primary endpoint, BPC-157 or TB-500 are mechanistically appropriate choices.

Don't. Oxytocin has no direct tissue-repair mechanism—it modulates neurological and behavioral pathways, not wound healing or angiogenesis. BPC-157 acts on VEGF and FGF signaling to promote collagen deposition and vascular growth in peripheral tissues. The two peptides operate on entirely different physiological systems, making side-by-side comparison in a tissue-repair protocol scientifically invalid. If your study involves both neurological and regenerative outcomes, treat them as separate dependent variables measured with independent peptide interventions—not as competing treatments for the same endpoint.

Mazdutide delivers faster hepatic fat clearance (58% vs 42% at 24 weeks) due to direct glucagon-driven oxidation, making it preferable for studies measuring liver-specific metabolic changes. Tirzepatide produces slightly higher total weight loss (20.9% vs 20.2%) but takes longer to reach peak effect (72 weeks vs 48 weeks). If the protocol timeline is under one year, mazdutide reaches comparable magnitude faster. If glycemic control is a co-primary endpoint, tirzepatide's GIP mechanism improves beta-cell function more robustly (A1C reductions of 2.58% vs 1.8%). Neither peptide is FDA-approved as a finished drug product. Both are available only through research synthesis or compounding under investigational protocols.

Cagrilintide's nausea originates from direct area postrema stimulation, not peripheral gastric effects. Standard ondansetron or metoclopramide often fails. The most effective mitigation strategy in our experience is extending the titration schedule from four-week to six-week intervals between dose increases, allowing central receptor desensitization to catch up with dose. If nausea persists beyond 12 weeks at a sub-therapeutic dose (below 1.2mg weekly), continuing the protocol rarely yields meaningful outcomes. The amylin receptor density required for sustained satiety isn't being reached.

Choose a long-acting injectable peptide like semaglutide or tirzepatide with weekly dosing. Daily oral administration of orforglipron requires daily handling and gavage in rodent models, introducing stress-related cortisol elevation that confounds metabolic endpoints like insulin sensitivity and weight trajectory. Weekly subcutaneous injections reduce handling frequency by 85%, minimizing stress-induced weight suppression that isn't attributable to the GLP-1 mechanism itself. This is particularly critical in studies measuring voluntary food intake or spontaneous activity. Repeated restraint stress suppresses these behaviors independently of drug effect.

SS-31 and CoQ10 act at different points in the electron transport chain. CoQ10 (ubiquinone) is a mobile electron carrier shuttling electrons from Complex I/II to Complex III. Supplementation increases the CoQ10 pool available for electron transfer. SS-31 doesn't provide electrons or cofactors; it prevents cardiolipin peroxidation that destabilizes the complexes themselves. If mitochondrial dysfunction stems from cofactor depletion (e.g., statin-induced CoQ10 deficiency), supplementation makes sense. If dysfunction stems from oxidative damage to membrane lipids. Which is the dominant mechanism in aging, ischemia, and neurodegenerative disease. SS-31 addresses the structural cause. The two are complementary, not redundant.

Reduce both compounds to 60–70% of their standalone effective doses. The combination produces additive appetite suppression through central (tesofensine) and peripheral (semaglutide) pathways, but side effects compound as well. Nausea from semaglutide intensifies with stimulant-driven dry mouth and insomnia from tesofensine. Standard approach: start semaglutide at 0.25mg weekly and tesofensine at 0.25mg daily, titrate both slowly over 8–12 weeks rather than the typical 4-week escalation.

This combination targets four pathways simultaneously. Amylin, GLP-1, GIP, and glucagon (if retatrutide is substituted). No published Phase 3 data exists yet for cagrilintide + tirzepatide specifically, but Phase 2 trials combining amylin analogs with dual agonists suggest additive weight loss of 3–6 percentage points over tirzepatide monotherapy. The nausea burden compounds significantly. Expect dropout rates above 20% during the first 12 weeks as both compounds titrate upward. This pairing makes sense only in research settings specifically designed to test maximum-tolerated multi-pathway activation, not in general metabolic studies.

Use sterile water only for single-dose vials that will be used immediately. Sterile water contains no preservative, so bacterial contamination becomes possible within hours of opening the vial. If you puncture the septum, draw a dose, and leave the vial for a second use, you're working with a potentially contaminated solution. The lack of benzyl alcohol means any bacteria introduced during the first draw will proliferate unchecked. This is acceptable for single-use protocols but unacceptable for multi-dose research where the same vial is accessed repeatedly over days or weeks.

Use SS-31 to address mitochondrial dysfunction in neurons. Age-related cognitive decline correlates with Complex I and IV deficiency in hippocampal and cortical mitochondria. Preclinical studies in aged mice showed SS-31 improved spatial memory retention by 35% compared to vehicle controls, likely by preserving synaptic ATP availability. Combine with BDNF-promoting interventions (exercise mimetics, 7,8-DHF) if synaptic plasticity is also impaired, but SS-31 alone targets the bioenergetic bottleneck that limits neuronal function in aging.

Use subcutaneous peptides to eliminate first-pass hepatic metabolism entirely. Orforglipron's hydroxylated metabolites retain partial GLP-1 receptor agonist activity and may exert direct effects on hepatic glucose output or lipid metabolism that aren't mediated by systemic GLP-1 receptor activation. If your research question isolates peripheral GLP-1 receptor effects (e.g., pancreatic beta-cell function, gastric motility, central appetite regulation), injectable peptides bypass the liver initially and avoid metabolite-mediated confounding. Studies examining hepatic steatosis or NAFLD progression should explicitly account for metabolite exposure when interpreting orforglipron data.

Discard the vial immediately. Cloudiness indicates particulate aggregation or bacterial contamination, both of which render the peptide unsafe and biologically inactive. Aggregation occurs when peptide molecules clump together due to temperature excursions, agitation, or pH shifts during reconstitution. Bacterial contamination appears as cloudiness or visible particles and signals a sterile technique failure at some point in the vial's handling history. Do not attempt to filter, re-dilute, or salvage a cloudy peptide solution. The molecular damage is irreversible.

Combine them—they target separate mechanisms. GLP-1 reduces intake through appetite suppression; 5-amino-1MQ shifts what's already in the system toward oxidation. No receptor overlap exists, and the pathways don't compete. The primary consideration is administration logistics: GLP-1 injections are weekly, 5-amino-1MQ requires daily dosing. Research protocols examining this combination started appearing in 2025, but no published data on safety or efficacy in humans exists as of 2026. Our team's assessment: mechanistically sound, but both agents must be dosed consistently for the interaction to matter.